Patient Satisfaction Following Multidisciplinary Cancer Care Assessment in Day Hospital: A Prospective Observational Study. (EVAQSAP-HDJ-BC)

April 24, 2026 updated by: Centre Hospitalier de Martigues

Evaluation and Analysis of Patient Satisfaction Following Multidisciplinary Complex Assessment in Day Hospital: Determinants and Implications for Continuous Quality Improvement

This study aims to evaluate patient satisfaction following a multidisciplinary "complex assessment" conducted in a Day Hospital setting at the Centre Hospitalier de Martigues. This assessment is part of routine care for patients diagnosed with cancer and scheduled to receive injectable anticancer treatment.

During this assessment, patients meet several healthcare professionals, including a pharmacist, dietitian, psychologist, social worker, and supportive care providers. The objective is to identify patient-specific needs and improve coordination of care at an early stage of the treatment pathway.

This is a prospective observational study based on an anonymous satisfaction questionnaire distributed to eligible adult patients after completion of the Day Hospital assessment. The primary objective is to assess overall patient satisfaction. Secondary objectives include evaluating satisfaction by specialty, identifying factors associated with satisfaction, and assessing the Net Promoter Score (NPS).

The results of this study are expected to help identify strengths and areas for improvement in multidisciplinary care, enhance patient-centered care, and support continuous quality improvement in oncology practice.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Cancer care requires a multidisciplinary and patient-centered approach to address the complex medical, psychological, and social needs of patients. In this context, a "complex assessment" program has been implemented in the Day Hospital (HDJ) of the Centre Hospitalier de Martigues for patients with various types of cancer (breast, gynecological, urological, digestive, hematological, and pulmonary) prior to initiation of injectable anticancer therapies.

This program involves coordinated consultations with multiple healthcare professionals, including a pharmacist, dietitian, psychologist, social worker, and supportive care providers. The aim is to identify vulnerabilities, optimize supportive care, and improve the overall patient care pathway.

This study is designed as a prospective observational study evaluating patient satisfaction with this multidisciplinary intervention. All eligible adult patients who undergo the Day Hospital complex assessment are invited to complete an anonymous satisfaction questionnaire. The questionnaire includes items related to the quality of care, interactions with healthcare professionals, organization of care, and overall satisfaction, as well as a Net Promoter Score (NPS).

The primary endpoint is the proportion of patients reporting high overall satisfaction. Secondary endpoints include satisfaction levels by healthcare professional category, identification of determinants associated with satisfaction, and evaluation of the NPS according to demographic and clinical characteristics.

Statistical analyses will include descriptive statistics, univariate and multivariate analyses to identify factors associated with patient satisfaction. Results from this study will provide valuable insights into patient experience and contribute to the continuous improvement of multidisciplinary oncology care in a non-university hospital setting.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
309

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

  • Name: MARTIN Gwenola healthcare manager of the day hospital, Diploma in Health Care Managem
  • Phone Number: +33-04 42 43 27 56
  • Email: Gwenola.MARTIN@ch-martigues.fr

Study Locations

  • France
    • Bouches du Rhone
      • Martigues, Bouches du Rhone, France, 13500
        • Recruiting
        • Centre Hospitalier de Martigues
        • Contact:
        • Contact:
          • MARTIN Gwenola healthcare manager of the day hospital, Diploma in Health Care Managem
          • Phone Number: +33 +33-04 42 43 27 56
          • Email: Gwenola.MARTIN@ch-martigues.fr
        • Principal Investigator:
          • GERARDIN Eric, doctor
        • Sub-Investigator:
          • CHEVALIER Thomas, doctor

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult patients with cancer treated at the Centre Hospitalier de Martigues and undergoing a multidisciplinary complex assessment in a Day Hospital setting prior to initiation of injectable anticancer therapy.

Description

Inclusion Criteria:

  • Adult patients (≥ 18 years old)
  • Patients undergoing a multidisciplinary "complex assessment" in a Day Hospital setting
  • Patients diagnosed with cancer and scheduled to receive injectable anticancer treatment
  • Ability to understand and complete the satisfaction questionnaire
  • Patients who have been informed and have not opposed participation

Exclusion Criteria:

  • Patients under 18 years of age
  • Patients unable to complete the questionnaire (e.g., severe cognitive impairment or major language barrier)
  • Patients who refuse participation
  • Patients with incomplete Day Hospital complex assessment
  • Patients under legal protection (guardianship or curatorship)

Patients under legal protection (guardianship or curatorship)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Patients undergoing multidisciplinary complex assessment in Day Hospital
Adult patients with cancer undergoing a multidisciplinary "complex assessment" in a Day Hospital setting prior to initiation of injectable anticancer treatment, including consultations with healthcare professionals and completion of a satisfaction questionnaire.
Other: Multidisciplinary Complex Assessment
Routine multidisciplinary assessment conducted in a Day Hospital setting involving consultations with healthcare professionals (pharmacist, dietitian, psychologist, social worker, and supportive care providers) as part of standard oncology care.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Overall Patient Satisfaction
Time Frame: At completion of the Day Hospital assessment (within 1 month after assessment)
Proportion of patients reporting high overall satisfaction following the multidisciplinary complex assessment, measured using an anonymous satisfaction questionnaire.
At completion of the Day Hospital assessment (within 1 month after assessment)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Centre Hospitalier de Martigues

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 10, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 15, 2029

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 15, 2029

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 24, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 24, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 1, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 1, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 24, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2024-A02062-45-EVAQSAP-HDJ-BC
  • 2024-A02062-45 (Other Identifier: ANSM)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared due to the observational nature of the study and institutional and regulatory constraints related to data protection and confidentiality. Only aggregated results will be reported in scientific publications.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Clinical Trials on Multidisciplinary Complex Assessment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings